Compare Illinois Tool Works Inc. (ITW) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illinois Tool Works Inc. vs 10X Genomics Inc — how do they compare? Illinois Tool Works Inc. trades at $273.57 (market cap $78.17B), while 10X Genomics Inc trades at $46.1 (market cap $5.48B). The key difference: Illinois Tool Works Inc. is far larger — about 14.3× 10X Genomics Inc's market cap, and Illinois Tool Works Inc. pays a 2.37% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| ITW | TXG | |
|---|---|---|
Market Cap | $78.17B | $5.48B |
Sector | Industrials | Health |
52-Week High | $299.60 | $45.80 |
52-Week Low | $241.07 | $11.34 |
Enterprise Value | $86.49B | $5.02B |
Dividend Yield | 2.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ITW trades at $271.58, down 1.62% today, with a bullish technical signal supported by moving averages. The company maintains strong profitability with a 19.32% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights mixed sentiment, with some analysts citing premium valuation concerns while others note growth prospects from enterprise initiatives and a potential bullish chart pattern.
Outlook remains cautiously optimistic with a consensus price target of $288.25 offering ~6% upside. Key risks include valuation sensitivity, organic sales pressure in some segments, and macroeconomic headwinds. The upcoming Q2 2026 earnings report on July 28, 2026, will be critical for validating growth trajectory amid analyst divergence.
TXG trades at $43.18, down 1.28% today, with a bullish technical signal and positive earnings momentum. The stock shows improving fundamentals with revenue growth to $642.82M in 2025 and narrowing losses, while maintaining a strong gross margin of 69.6%. Recent acquisitions and partnerships with Cleveland Clinic demonstrate strategic expansion in genomic diagnostics.
The outlook remains cautiously optimistic with analyst consensus at Buy (45%) and price target of $39.14. Key risks include continued negative profitability metrics and high valuation multiples, while catalysts include upcoming Q2 2026 earnings and platform adoption growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
